

Mouse Anti-Vimentin [V9]: MC0268, MC0268RTU7

Intended Use: For Research Use Only

Description: Anti-vimentin is of limited value as a diagnostic tool; however, when used in combination with other antibodies (in panels) it is useful for the subclassification of a given tumor. Expression of vimentin, when used in conjunction with anti-keratin, is helpful when distinguishing melanomas from undifferentiated carcinomas and large cell lymphomas. All melanomas and Schwannomas react strongly with anti-vimentin. This antibody recognizes a 57 kD intermediate filament. It labels a variety of mesenchymal cells, including melanocytes, lymphocytes, endothelial cells, and fibroblasts. Non-reactivity of anti-vimentin is often considered more useful than its positive reactivity, since there are a few tumors that do not contain vimentin, e.g. hepatoma and seminoma. Anti-vimentin is also useful as a tissue process control reagent.

Specifications

Clone: V9
Source: Mouse
Isotype: IgG/k
Reactivity: Human
Localization: Cytoplasm

Formulation: Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)

Storage: Store at 2°-8°C

Applications: IHC

Package:

Description	Catalog No.	Size
Vimentin Concentrated	MC0268	1 ml
Vimentin Prediluted	MC0268RTU7	7 ml

IHC Procedure


Positive Control Tissue: Tonsil Concentrated Dilution: 100-300

Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes

using water bath at 95°-99°C

Incubation Time and Temp: 30-60 minutes @ RT

Detection: Refer to the detection system manual * Result should be confirmed by an established diagnostic procedure.



FFPE human kidney stained with anti-Vimentin using DAB

References:

- 1. Expression of CD82 in human trophoblast and its role in trophoblast invasion. Zhang Q, et al. PLoS One 7:e38487, 2012. Macrophage secretory products induce an inflammatory phenotype in hepatocytes. Melino M, et al. World J Gastroenterol 18:1732-44, 2012.
- 2. Bone marrow-derived cells from male donors do not contribute to the endometrial side population of the recipient. Cervelló I, et al. PLoS One 7:e30260, 2012.

Doc. 100-MC0268

Rev. A

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 510-509-3153 www.medaysis.com © Medaysis Company